Keywords: اینفیلیکسیماب; Pre-clinical Crohn's disease; Early diagnosis; Natural history; Infliximab; T-regs;
مقالات ISI اینفیلیکسیماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: اینفیلیکسیماب; CD; Crohn's disease; Anti-TNF-α; anti-tumor necrosis factor-α; IFX; infliximab; PCDAI; Pediatric Crohn's Disease Activity Index; ATI; anti-infliximab-antibodies; PDAI; Perianal Crohn's Disease Activity Index; QoL; quality of life; UC; ulcerative colitis
Keywords: اینفیلیکسیماب; Biological products; Biosimilar pharmaceuticals; Post marketing product surveillance; Infliximab; Inflammatory bowel disease;
Keywords: اینفیلیکسیماب; Psoriatic arthritis; Quality-of-life; SF-36; EQ-5D; Biological therapies; InfliximabArtritis psoriásica; Calidad de vida; SF-36; EQ-5D; Terapias biológicas; Infliximab
Keywords: اینفیلیکسیماب; Psoriatic arthritis; Quality-of-life; SF-36; EQ-5D; Biological therapies; InfliximabArtritis psoriásica; Calidad de vida; SF-36; EQ-5D; Terapias biológicas; Infliximab
Keywords: اینفیلیکسیماب; Rheumatoid arthritis; TNF-α inhibitors; Retention rate; Etanercept; Adalimumab; Infliximab;
Keywords: اینفیلیکسیماب; Crohn disease; Infliximab; C-reactive protein; Prognosis; Treatment outcome;
Keywords: اینفیلیکسیماب; anti-infliximab antibodies; dose escalation; dose intensification; human antichimeric antibodies; infliximab; methotrexate; psoriasis;
Keywords: اینفیلیکسیماب; Colitis ulcerosa; Brote grave; Tratamiento; Infliximab; CiclosporinaUlcerative colitis; Severe; Treatment; Infliximab; Cyclosporine
Keywords: اینفیلیکسیماب; Ulcerative colitis; Infliximab; Adalimumab; Certolizumab pegol; Appropriateness; Treatment discontinuation;
Keywords: اینفیلیکسیماب; Remicade; Drug Holiday; Antidrug Antibody; Pharmacokinetics; ATI; antibodies to infliximab; CI; confidence interval; CRP; C-reactive protein; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IMM; immunomodulator; IR; infusion reaction;
Keywords: اینفیلیکسیماب; Ulcerative colitis; Tacrolimus; Ciclosporin; Infliximab; Inflammatory bowel disease;
Keywords: اینفیلیکسیماب; Adalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Intensificación; Cambio (switching); Fracaso secundarioAdalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Escalation; Switching; Maintenance failure
Keywords: اینفیلیکسیماب; Adalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Escalation; Switching; Maintenance failureAdalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Intensificación; Cambio (switching); Fracaso secundario
Keywords: اینفیلیکسیماب; ADA; adalimumab; CD; Crohn disease; CDAI; Crohn's Disease Activity Index; CrI; credible interval; CZP; certolizumab pegol; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IL-12/23; interleukin 12/23; NAT; natalizumab; OR; odds ratio;
Keywords: اینفیلیکسیماب; A; absenteeism; ADA; adalimumab; CD; Crohn's disease; CPC; conventional proctocolectomy and Brooke ileostomy; CZP; certolizumab pegol; HPWAW; hours per week actually worked; HPWFP; productivity and hours per week fully productive; IBD; inflammatory bowel
Keywords: اینفیلیکسیماب; Anti-tumor necrosis factor; Infliximab; Adalimumab; Golimumab; Certolizumab pegol; Complications; Infusion reactions; Autoimmune disease;
Keywords: اینفیلیکسیماب; Chronic refractory pouchitis; Pouch fistulae; Infliximab;
Keywords: اینفیلیکسیماب; Sarcoidosis; Bronchiectasis; Infliximab; Prednisone;
Keywords: اینفیلیکسیماب; Autoimmune hepatitis; Infliximab; Rescue treatment;
Keywords: اینفیلیکسیماب; TNF; tumor necrosis factor; MRI; magnetic resonance imaging; CT; computerized tomography; PFT; pulmonary function test; LN; lymph node; CNS; central nervous system; IFX; infliximab; FEV1; forced expiratory volume in 1Â s; FVC; forced vital capacity; TLC;
Keywords: اینفیلیکسیماب; IBD; Inflammatory Bowel Disease; CD; Crohn's disease; hsCRP; high sensitivity CRP; CDAI; Crohn's Disease Activity Index; CDEIS; Crohn's Disease Endoscopic Index of Severity; Serum calprotectin; Crohn's disease; Biomarker; Relapse prediction; Infliximab;
Keywords: اینفیلیکسیماب; Crohn's disease; Post-operative recurrence; Infliximab; Azathioprine;
Keywords: اینفیلیکسیماب; Ulcerative colitis; Ileal pouch anal anastomosis; IPAA; Infliximab; Complications; Pelvic sepsis;
Keywords: اینفیلیکسیماب; Infliximab; Adalimumab; Response; Growth; Inflammatory markers;
Keywords: اینفیلیکسیماب; Depression; Infliximab; Tumor necrosis factor; Gene expression; Gluconeogenesis;
Keywords: اینفیلیکسیماب; Behçet's; Pulmonary artery aneurysm; Vasculitis; Tumour necrosis factor-α; Infliximab; Anti-TNF
Keywords: اینفیلیکسیماب; ulcerative colitis; primary sclerosing cholangitis; inflammatory bowel disease; infliximab; ischemic stroke; demyelinating disease; acute hemorrhagic leukoencephalitis; AHLE
Keywords: اینفیلیکسیماب; TNF, tumor necrosis factor alpha; CD, Crohn's disease; HBI, Harvey–Bradshaw index; 95% CI, 95% confidence intervalCrohn's disease; De-intensification; Loss of response; Tumour necrosis factor; Infliximab; AdalimumabEnfermedad de Crohn; Desintensificación;
Keywords: اینفیلیکسیماب; Ipilimumab; Colitis; Adverse event; Infliximab; MelanomaIpilimumab; Colitis; Efecto adverso; Infliximab; Melanoma
Keywords: اینفیلیکسیماب; Cellular proliferation; Infliximab; Mucosal healing; TNF-α; Wound repair
Keywords: اینفیلیکسیماب; Efficacy; Effectiveness; Inflammatory bowel disease; Infliximab; AdalimumabEficacia; Efectividad; Enfermedad inflamatoria intestinal; Infliximab; Adalimumab
Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAgâ) on anti-TNF therapy have a low rate of reactivation
Keywords: اینفیلیکسیماب; IMID; immune-mediated inflammatory diseases; anti-HBc; antibody to hepatitis B core antigen; HBsAg; hepatitis B surface antigen; IBD; inflammatory bowel disease; TB; tuberculosis; HBV; hepatitis B virus; RA; rheumatoid arthritis; AGA; American Gastroenter
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease
Keywords: اینفیلیکسیماب; Adalimumab; Crohn disease; Infliximab; Ulcerative Colitis;
Efficacy of infliximab in refractory posterior uveitis in Behcet's disease patients
Keywords: اینفیلیکسیماب; Behçet's disease; Posterior uveitis; Retinal vasculitis; Infliximab;
Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease
Keywords: اینفیلیکسیماب; Kawasaki disease; Coronary artery aneurysm; Infliximab; Coronary artery regression; Tumor necrosis factor-alpha; Intravenous immunoglobulin;
Clinical utility of anti-MOG antibody testing in a Danish cohort
Keywords: اینفیلیکسیماب; Anti-myelin oligodendrocyte glycoprotein antibody; Multiple sclerosis; NMOSD; CRION; Infliximab;
Simple and ultra-fast recognition and quantitation of compounded monoclonal antibodies: Application to flow injection analysis combined to UV spectroscopy and matching method
Keywords: اینفیلیکسیماب; Bvz; bevacizumab; CS; control standard; ifx; infliximab; PCA; principal component analysis; QC; quality control; rtx; rituximab; SEN; sensitivity; SPE; specificity; trz; trastuzumab; Monoclonal antibody; Qualitative control; Quantitative control; Second d
Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease
Keywords: اینفیلیکسیماب; AC; anterior chamber; ADA; adalimumab; BCVA; best-corrected visual acuity; BD; Behçet disease; CME; cystoid macular edema; FA; fluorescein angiography; IFX; infliximab; IQR; interquartile range; SD; standard deviation; SUN; Standardization of Uveitis Nom
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)
Keywords: اینفیلیکسیماب; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infection; Infliximab; Prevention; Tuberculosis; Tumour necrosis factor-α;
A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease
Keywords: اینفیلیکسیماب; Adalimumab; Anti-TNF naïve; Biologics; Crohn's disease; Children; Infliximab; Paediatric; Adalimumab; Naive a anti-TNF; Biológicos; Enfermedad de Crohn; Niños; Infliximab; Pediátrico;
Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients
Keywords: اینفیلیکسیماب; Behçet's disease; Angio-Behçet's; Vasculitis; Anti-TNFα; Treatment; Infliximab; Major vessel disease; TNFα; Tumor Necrosis Factor; BD; Behcet's disease; PAA; Pulmonary Artery Aneurysm; PAI; Pulmonary Artery Involvement; ICV; Inferior Vena Cava; BCS; B
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France
Keywords: اینفیلیکسیماب; Infliximab; CT-P13; Biosimilar; Rheumatoid Arthritis; Axial Spondyloarthritis; Crohn's disease; Ulcerative Colitis; Uveitis; Switch;
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis
Keywords: اینفیلیکسیماب; Polymyositis; Dermatomyositis; Infliximab; TNF inhibitor;
Stability of infliximab solutions in different temperature and dilution conditions
Keywords: اینفیلیکسیماب; Infliximab; Monoclonal antibody; Chemistry techniques; Analytical; Stability; Dilution; Temperature;
Partial cauda equina syndrome after an uneventful minimally invasive microdiscectomy in a patient with Crohn's disease
Keywords: اینفیلیکسیماب; Autoimmune disease; Crohn's disease; Infliximab; Remicade; Minimally invasive microdiscectomy; Cauda equina syndrome;
Altered activation of peripheral CD8+ T cells in pediatric Crohn's disease
Keywords: اینفیلیکسیماب; Crohn's disease; Calcium influx; CD8; Infliximab; T cell;
Epstein-Barr virus-positive mucocutaneous ulcer in Crohn's disease. A condition to consider in immunosuppressed IBD patients
Keywords: اینفیلیکسیماب; Crohn's disease; EBV mucocutaneous ulcer; Infliximab;
Enfermedad inflamatoria intestinal como efecto paradójico del tratamiento con anti-TNF-α
Keywords: اینفیلیکسیماب; Enfermedad inflamatoria intestinal; Efectos paradójicos; Anti-TNF-α; Infliximab; Etanercept; Adalimumab; Inflammatory bowel disease; Paradoxical effects; Anti-TNF-α therapies; Infliximab; Etanercept; Adalimumab;
Short paperProposal for an anti-TNF-exit strategy based on trough serum level
Keywords: اینفیلیکسیماب; Exit strategy; TSL (trough serum level); Infliximab; IBD; Inflammatory bowel disease; UC; Ulcerative colitis; CD; Crohn's disease; TSL; Trough serum level; T0; Time point of discontinuation;